Search research articles
Contact Us
Filters
Showing results (1-10 of 33) with videos related to
Page
of 4
Sort By:
Infectious Diseases and Therapy
|
April 19, 2025
An Economic Model to Assess the Cost Impact of Using Xpert Carba-R to Screen Carbapenemase-Producing Enterobacterales in Comparison with Standard of Care, in a National Health Service Setting
Mondher Toumi, Ruth Pulikottil-Jacob, Karina Watts, et al.
Patient Preference and Adherence
|
April 6, 2023
Impact of Potential Symptoms and Risks Associated with Acid Sphingomyelinase Deficiency on Patients and Caregivers: A Best-Worst Scaling Study
Carol Mansfield, Lubomyra Nalysnyk, Dhaivat Joshi, et al.
Advances in Therapy
|
March 10, 2023
Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims Analysis
Ruth Pulikottil-Jacob, Michael L Ganz, Marie Fournier, et al.
Pharmacoeconomics
|
October 28, 2016
Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom
Lindsay Claxton, Robert Hodgson, Matthew Taylor, et al.
Advances in Therapy
|
February 12, 2017
The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis
Andriy Danyliv, Julie Glanville, Rachael McCool, et al.
Trials
|
June 3, 2014
Six weeks of home enteral nutrition versus standard care after esophagectomy or total gastrectomy for cancer: study protocol for a randomized controlled trial
David J Bowrey, Melanie Baker, Vanessa Halliday, et al.
Molecular Genetics and Metabolism Reports
|
March 12, 2024
Diagnostic odyssey for patients with acid sphingomyelinase deficiency (ASMD): Exploring the potential indicators of diagnosis using quantitative and qualitative data
Andrew Doerr, Maliha Farooq, Chad Faulkner, et al.
Advances in Therapy
|
July 27, 2016
The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK
Wrik Ghosh, Rose Wickstead, Lindsay Claxton, et al.
Scientific Reports
|
October 26, 2021
Impact and burden of acid sphingomyelinase deficiency from a patient and caregiver perspective
Robin Pokrzywinski, Asha Hareendran, Luba Nalysnyk, et al.
Lancet (London, England)
|
September 12, 2014
Understanding why children die in high-income countries
Peter Sidebotham, James Fraser, Teresa Covington, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 33) with videos related to
Sort By:
Page
of 4
Infectious Diseases and Therapy
|
April 19, 2025
An Economic Model to Assess the Cost Impact of Using Xpert Carba-R to Screen Carbapenemase-Producing Enterobacterales in Comparison with Standard of Care, in a National Health Service Setting
Mondher Toumi, Ruth Pulikottil-Jacob, Karina Watts, et al.
Patient Preference and Adherence
|
April 6, 2023
Impact of Potential Symptoms and Risks Associated with Acid Sphingomyelinase Deficiency on Patients and Caregivers: A Best-Worst Scaling Study
Carol Mansfield, Lubomyra Nalysnyk, Dhaivat Joshi, et al.
Advances in Therapy
|
March 10, 2023
Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims Analysis
Ruth Pulikottil-Jacob, Michael L Ganz, Marie Fournier, et al.
Pharmacoeconomics
|
October 28, 2016
Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom
Lindsay Claxton, Robert Hodgson, Matthew Taylor, et al.
Advances in Therapy
|
February 12, 2017
The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis
Andriy Danyliv, Julie Glanville, Rachael McCool, et al.
Trials
|
June 3, 2014
Six weeks of home enteral nutrition versus standard care after esophagectomy or total gastrectomy for cancer: study protocol for a randomized controlled trial
David J Bowrey, Melanie Baker, Vanessa Halliday, et al.
Molecular Genetics and Metabolism Reports
|
March 12, 2024
Diagnostic odyssey for patients with acid sphingomyelinase deficiency (ASMD): Exploring the potential indicators of diagnosis using quantitative and qualitative data
Andrew Doerr, Maliha Farooq, Chad Faulkner, et al.
Advances in Therapy
|
July 27, 2016
The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK
Wrik Ghosh, Rose Wickstead, Lindsay Claxton, et al.
Scientific Reports
|
October 26, 2021
Impact and burden of acid sphingomyelinase deficiency from a patient and caregiver perspective
Robin Pokrzywinski, Asha Hareendran, Luba Nalysnyk, et al.
Lancet (London, England)
|
September 12, 2014
Understanding why children die in high-income countries
Peter Sidebotham, James Fraser, Teresa Covington, et al.
Page
of 4